Eurofins Scientific SE, a global leader in bioanalytical testing, recently announced the successful raising of €500m in its latest senior unsecured Euro-denominated public bond issuance. The Bonds, with a 7.5-year maturity and an annual fixed rate coupon of 3.875%, were well received and oversubscribed. The proceeds from this issuance will be used to finance Eurofins’ planned acquisition of related party-owned sites and for general corporate purposes. CEO Dr.
Gilles Martin expressed satisfaction with the results, highlighting investor confidence in Eurofins’ strategic objectives. The Bonds, to be listed on the Luxembourg stock exchange, signify a vote of confidence in Eurofins’ commitment to being a leading network of laboratories in various fields. With a global presence and a wide range of services, Eurofins continues to invest in digitalization and state-of-the-art facilities to meet the evolving needs of clients and regulatory standards.
Read more from finance.yahoo.com